Daratumumab plus VRd in Japanese transplant-ineligible/deferred NDMM patients: Japanese subgroup of the CEPHEUS trial - PubMed
7 hours ago
- #Multiple Myeloma
- #Japan
- #Clinical Trial
- Phase 3 CEPHEUS trial evaluated D-VRd (daratumumab plus bortezomib, lenalidomide, dexamethasone) versus VRd in transplant-ineligible/deferred NDMM patients.
- Japanese subgroup analysis (D-VRd: n=9; VRd: n=13) showed higher MRD negativity (77.8% vs. 46.2%) and complete response or better rates (88.9% vs. 76.9%) with D-VRd.
- At 59-month follow-up, median progression-free survival was not reached; D-VRd reduced risk of progression/death with hazard ratio of 0.34.
- Safety profile in Japanese patients was consistent with global population, supporting D-VRd use in this demographic.